← All trials
NCT00709371
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2008
- Primary completion
- Apr 1, 2009
- Completion date
- Jul 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 729
- Arms / groups
- 6 / —
- Source
- AACT · pre-existing
Sponsors
- Orexigen Therapeutics, IncLead sponsor
- The Cooper InstituteOverall official - principal investigator
- Mercy ResearchOverall official - principal investigator
- University of VermontOverall official - principal investigator
- MRA Clinical ResearchOverall official - principal investigator
- Internal Medicine Associates of CharlotteOverall official - principal investigator
- FutureCare StudiesOverall official - principal investigator
- Washington Center for Weight Management and ResearchOverall official - principal investigator
- Radiant ResearchOverall official - principal investigator
- Summit Research NetworkOverall official - principal investigator
- University of NevadaOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- Partners in HealthOverall official - principal investigator
- Wake Research AssociatesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.